Core Viewpoint - ICON Public Limited Company is currently facing scrutiny due to an investigation into its accounting practices, which has significantly impacted its stock price and raised concerns among investors [2][3][6] Financial Performance - ICON is scheduled to release its quarterly earnings on March 18, 2026, with analysts estimating earnings per share (EPS) of $3.24 and projected revenue of approximately $2 billion [2][6] - Prior to the investigation, ICON's stock was trading confidently, with expected full-year revenue between $8.05 billion and $8.1 billion and adjusted EPS guidance of $13.00 to $13.20 [4] Stock Price Impact - Following the announcement of the internal investigation, ICON's stock price dropped by $53.06 per share, marking a 39.85% decrease and closing at $80.08 per share [3][4] - This decline erased billions in shareholder value and represents one of the largest percentage drops in the CRO sector in recent years [4] Valuation Metrics - Despite the ongoing challenges, ICON's financial metrics indicate a price-to-earnings (P/E) ratio of approximately 13.10 and a price-to-sales ratio of about 0.96, suggesting efficient conversion of operating cash flow into enterprise value [5][6] - The enterprise value to sales ratio is around 1.34, and the enterprise value to operating cash flow ratio is approximately 9.22 [5]

Core Insights - Charles River Laboratories International, Inc. (NYSE:CRL) is recognized as one of the top mid-cap AI stocks to invest in according to hedge funds, with a price target increase from $197 to $251 by TD Cowen, indicating a potential upside of 38.49% [1] - The firm anticipates solid quarterly results for Q4 and believes that the 2026 guidance could clarify operating conditions for investors [2] - A new gene therapy collaboration with Gazi University has been announced, focusing on advancing research for Hyperphosphatemic tumoral calcinosis (HTC) [3][4] Company Developments - The collaboration with Gazi University involves providing plasmid DNA for AAV production and support for in vitro efficacy studies, aimed at early-stage gene therapy programs [3][4] - Kerstin Dolph, Corporate Senior Vice President, emphasized the importance of this collaboration in transforming innovative concepts into real-world therapies [4] - Charles River Laboratories operates in various segments including Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, and has a global presence [4]

Core Insights - Charles River Laboratories International, Inc. (CRL) is valued at a market cap of $10.8 billion and operates as a global contract research organization (CRO) supporting drug discovery and development for various clients [1] Financial Performance - CRL is expected to announce its fiscal Q4 earnings for 2025 soon, with analysts predicting a profit of $2.33 per share, which represents a 12.4% decrease from $2.66 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast CRL to report a profit of $10.22 per share, down 1% from $10.32 per share in fiscal 2024, but expect a rebound with a growth of 4.9% year over year to $10.72 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, CRL's stock has increased by 32.5%, outperforming the S&P 500 Index's 16.9% increase and the Health Care Select Sector SPDR Fund's 10.4% rise [4] - On December 22, shares of CRL rose about 3% following an upgrade to "Buy" by BofA Securities and the closure of an SEC investigation into the company's primate sourcing practices without enforcement action, alleviating investor concerns [5] Analyst Ratings - Wall Street analysts maintain a moderately optimistic outlook on CRL's stock, with an overall "Moderate Buy" rating; among 16 analysts, 11 recommend "Strong Buy" and five suggest "Hold" [6] - The stock currently trades above the mean price target of $209.57, with a Street-high target of $260 indicating an upside potential of 18.3% from current market prices [6]

Core Insights - Inotiv achieved a remarkable revenue growth of 448% from fiscal year 2021 to fiscal year 2024, earning a spot at 182 on the Deloitte Technology Fast 500™ ranking [1][2] - The company's success is attributed to its client-focused approach, strategic acquisitions, and the development of complementary services that enhance client support [2] - Inotiv has been recognized as a Deloitte Technology Fast 500™ winner for three consecutive years, reflecting both client trust and team dedication [2] Company Overview - Inotiv, Inc. is a leading contract research organization that provides nonclinical and analytical drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs and medical devices to market [5] - The company aims to support researchers in realizing the full potential of their critical research and development projects, contributing to a healthier and safer world [5] Industry Context - The Deloitte Technology Fast 500™ ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America based on percentage revenue growth [3] - The 2025 rankings highlight a mix of established leaders and new innovators, with private companies showing significant agility and growth potential in competitive markets [2][3]

Core Insights - Fortrea has appointed Agnieszka (Aggie) M. Gallagher as general counsel, responsible for the company's legal strategy and operations, succeeding J. Stillman Hanson [1][2] - Gallagher brings over 25 years of experience in the life sciences sector, having held leadership roles in various companies including Standard Biotools, Orasure Technologies, and Alnylam Pharmaceuticals [2][3] - Gallagher expressed enthusiasm about joining Fortrea during a pivotal moment and looks forward to collaborating with the global team to accelerate innovative treatments [4] Company Overview - Fortrea is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [1][4] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [4] - Fortrea operates in approximately 100 countries, delivering focused and agile solutions to its customers globally [4]

Core Viewpoint - Fortrea reported solid financial performance in Q3 2025, with revenue growth and a commitment to operational excellence despite ongoing challenges [2][3]. Financial Results - Revenue for Q3 2025 was $701.3 million, an increase from $674.9 million in Q3 2024, representing a growth of approximately 3.9% [3]. - The GAAP net loss for Q3 2025 was $(15.9) million, with a diluted loss per share of $(0.17), an improvement from a net loss of $(18.5) million and diluted loss per share of $(0.21) in Q3 2024 [4]. - Adjusted net income for Q3 2025 was $11.7 million, with a diluted income per share of $0.12, compared to $20.7 million and $0.23 in Q3 2024 [4]. - Adjusted EBITDA for Q3 2025 was $50.7 million, down from $64.2 million in Q3 2024 [4]. Year-To-Date Results - Year-to-date revenue for the first nine months of 2025 was $2,062.9 million, compared to $1,999.4 million in the same period of 2024, indicating a growth of approximately 3.2% [6]. - Year-to-date GAAP net loss was $(953.7) million, including a non-cash goodwill impairment charge of $797.9 million, compared to a net loss of $(197.6) million in the same period of 2024 [7]. - Adjusted net income year-to-date was $31.2 million, with a diluted income per share of $0.34, compared to $13.5 million and $0.15 in the same period of 2024 [7]. Backlog and Book-to-Bill Ratio - As of September 30, 2025, the backlog was $7,644 million, with a book-to-bill ratio of 1.13x for the quarter [5][10]. Full-Year Guidance - The company raised its revenue guidance for the full year 2025 to a range of $2,700 million to $2,750 million and narrowed adjusted EBITDA guidance to a range of $175 million to $195 million [9][10].

Core Insights - The Optimist Fund achieved a return of +9.1% in Q3 2025, significantly outperforming its benchmark [5] - The fund's year-to-date return stands at 44.5%, compared to the benchmark's 11.1% [5] - The fund anticipates continued growth opportunities over the next three and a half years, similar to recent performance [4] Fund Performance - The fund's performance over various periods shows significant volatility, with a notable recovery from a -51.4% return in 2022 to 82.9% in 2023 [5] - Compound returns as of September 30, 2025, indicate strong performance across 1-year (61.2%), 2-year (65.6%), and 3-year (61.9%) periods [5] Top Contributors - **Wayfair**: Revenue increased by approximately 5% year-over-year to $3.27 billion, marking its fastest growth since Q1 2021. Adjusted EBITDA reached $205 million, indicating a margin above 6% for the first time since Q2 2021 [7][8][9] - **ThredUp**: Revenue rose 16% year-over-year to $77.7 million, with adjusted EBITDA increasing by around 100%. Active buyers grew by 17% to 1.47 million [10][11][12] - **Carvana**: Retail units sold increased by 41% year-over-year to 143,280 vehicles, with total revenue rising 42% to $4.84 billion. Adjusted EBITDA reached $601 million, reflecting a 12.4% margin [13][14][15] Top Detractors - **Monday.com**: Despite a 27% increase in revenue, the company reduced its second-half 2025 revenue guidance due to weaker performance marketing trends, causing investor concerns [20][21][22] - **Fiverr**: Results were below expectations, leading to a reduction in position size despite maintaining an attractive risk/reward profile [25][26] Portfolio Composition - The top 10 holdings comprise approximately 85% of the portfolio, including ThredUp, Monday.com, Carvana, Uber, Wayfair, DoorDash, First Advantage, Fiverr, Latham Group, and Medpace [27] Notable Changes - The fund exited positions in HelloFresh and Revolve due to management changes and reduced confidence in growth prospects, reallocating capital to more promising opportunities [29][30] Company Insights - **Medpace**: A leading contract research organization (CRO) focused on small and mid-sized biotech companies, showing strong revenue growth of 14.2% year-over-year to $603.3 million [31][18][35] - The company has a disciplined capital allocation strategy, with a history of share repurchases during market downturns, enhancing long-term growth potential [34][35]

Market Overview - Mid-cap stocks advanced in Q3, with the Russell Midcap Index returning 5.3%, driven by monetary policy shifts and stabilizing earnings [2] - Value stocks outperformed growth stocks, with the Russell Midcap Value Index returning 6.2% compared to 2.8% for the Russell Midcap Growth Index [2] Policy and Sentiment - Investor sentiment improved due to the passage of the One Big Beautiful Bill and progress on trade agreements, reducing policy uncertainty [3] - Earnings estimates stabilized, particularly in technology and AI sectors, despite some economic segments remaining weak [3] Portfolio Performance - The ClearBridge Mid Cap Strategy outperformed its benchmark, with strong stock selection in consumer staples and health care [4] - Performance Food Group and Casey's General Stores were key contributors, benefiting from strategic initiatives and strong execution [4] Sector Contributions - Health care was a significant driver of outperformance, with companies like argenx and Alnylam Pharmaceuticals showing strong results [5] - AppLovin's stock rallied due to excitement around its new e-commerce business, indicating potential for cash flow growth [6] Challenges - Stock selection in consumer discretionary and materials sectors posed challenges, with Chewy and Crown Holdings underperforming [7][8] New Positions - A new position was initiated in QXO, a building materials distribution platform, expected to consolidate the industry and improve efficiency [9] - Bio-Techne was also added to the portfolio, capitalizing on recent weakness and offering durable revenue streams [10] Exits - The position in ATS Corporation was exited due to leadership changes raising concerns about future performance [11] Outlook - The outlook for mid-cap equities remains constructive, with expectations for selective stock picking amid potential volatility [13] - The focus will be on businesses with competitive advantages and resilient cash flows [14] Portfolio Highlights - The ClearBridge Mid Cap Strategy saw contributions from 10 of 11 sectors, with IT and industrials being the largest contributors [16] - Stock selection in consumer staples, IT, and health care sectors positively impacted performance, while consumer discretionary and materials sectors detracted [17]

Core Insights - Fortrea Holdings Inc. is identified as a cheap stock with potential for growth over the next five years, with Barclays raising its price target to $8 from $6 while maintaining an Underweight rating [1][3] Financial Performance - In Q2, Fortrea reported quarterly revenue of $710.3 million, reflecting a year-over-year increase of 7.23% [1][2] - The company achieved an Adjusted EBITDA of $54.9 million and an adjusted net income per diluted share of $0.19, prompting management to raise its full-year 2025 revenue guidance to a range of $2.6 to $2.7 billion [2] - Despite revenue growth, Fortrea recorded a GAAP net loss of $374.9 million, or $4.14 per diluted share, primarily due to a non-cash goodwill impairment charge of $309.1 million [3] Business Overview - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers [4] - The company's backlog stood at $7.547 billion, indicating a strong pipeline of future business [3] - Fortrea affirmed that its cost-saving initiatives are on track, which may enhance future profitability [3]

Core Insights - The healthcare sector requires companies to develop unique technologies or products to maintain long-term success and withstand competition [1] - Identified companies with potential for sustained success include argenx SE, ICON plc, and Edwards Lifesciences Corp [2] Company Summaries Argenx SE - Argenx specializes in treatments for autoimmune diseases, particularly with its FDA-approved drug efgartigimod (VYVGART), which targets chronic autoimmune conditions like myasthenia gravis [2][3] - The company reported a 97% year-over-year increase in product sales, indicating strong market demand and growth potential [4] - All 21 analysts covering argenx have assigned a Buy rating, reflecting confidence in its future performance [4] ICON plc - ICON is a leading contract research organization (CRO) that provides outsourced development and commercialization services, particularly excelling in decentralized clinical trials [6][7] - Following its $12 billion acquisition of PRA Health Sciences, ICON has solidified its position as one of the largest CROs globally [6] - The company has demonstrated revenue resilience, with a commitment to shareholder value through $250 million in share repurchases and an authorization for up to $1 billion in additional buybacks [8] Edwards Lifesciences Corp - Edwards Lifesciences is a leader in medical devices for structural heart disease, particularly known for its transcatheter aortic valve replacement (TAVR) system [9][10] - The company has a strong market share in TAVR, with a favorable shift towards this minimally invasive procedure among surgeons [10] - Despite a slight decline in earnings per share year-over-year, analysts project over 12% earnings growth for the upcoming year, supported by robust R&D investments [11][12]